Findings

What do systematic reviews say?

4,710 questions · 14,842 findings · 1,394 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,880 · 19.4%GRADE not reported 1,413 · 9.5%Very low 3,103 · 20.9%Low 3,870 · 26.1%Moderate 2,663 · 17.9%High 913 · 6.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Foam sclerotherapy vs placebo

Persistence of symptoms · participants with varicose veinsa

1 finding from 1 review

Injection sclerotherapy for varicose veins 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 223 participants
Low

Foam sclerotherapy vs placebo

Recurrent varicose veins · participants with varicose veinsa

The review found no eligible studies for this question.

1 finding from 1 review

Injection sclerotherapy for varicose veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Opioids vs Placebo, no intervention or usual care (with or without placebo)

Treatment failure To discharge · newborn infants with opioid withdrawal

It is very uncertain whether opioid changes treatment failure To discharge compared with placebo or no treatment / usual care (very low certainty).

1 finding from 1 review

Opioid treatment for opioid withdrawal in newborn infants 2021 · Cochrane Headline outcomes only
RR 1.29 [0.41, 4.07]
1 study · 80 participants
Very low

Opioids vs Placebo, no intervention or usual care (with or without placebo)

Seizures To discharge · newborn infants with opioid withdrawal

1 finding from 1 review

Opioid treatment for opioid withdrawal in newborn infants 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Opioids vs Placebo, no intervention or usual care (with or without placebo)

Neonatal or infant mortality · newborn infants with opioid withdrawal

The review found no eligible studies for this question.

1 finding from 1 review

Opioid treatment for opioid withdrawal in newborn infants 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Opioids vs Placebo, no intervention or usual care (with or without placebo)

Neurodevelopmental disability · newborn infants with opioid withdrawal

The review found no eligible studies for this question.

1 finding from 1 review

Opioid treatment for opioid withdrawal in newborn infants 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Opioids vs Placebo, no intervention or usual care (with or without placebo)

Length of hospital stay · newborn infants with opioid withdrawal

1 finding from 1 review

Opioid treatment for opioid withdrawal in newborn infants 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Opioids vs Placebo, no intervention or usual care (with or without placebo)

Days treatment · newborn infants with opioid withdrawal

1 finding from 1 review

Opioid treatment for opioid withdrawal in newborn infants 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Opioids vs Placebo, no intervention or usual care (with or without placebo)

Adverse events (treatment related) To discharge · newborn infants with opioid withdrawal

The review found no eligible studies for this question.

1 finding from 1 review

Opioid treatment for opioid withdrawal in newborn infants 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Aspirin vs placebo

Graft thrombosis (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft

Aspirin showed no clear difference in graft thrombosis (28 days to 18 months) compared with placebo (low certainty).

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
OR 0.4 [0.07, 2.25]
3 studies · 175 participants
Low

Dipyridamole vs placebo

Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dipyridamole vs placebo

Complications (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

Dipyridamole vs placebo

Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dipyridamole plus aspirin vs placebo

Graft thrombosis (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

Dipyridamole plus aspirin showed no clear difference in graft thrombosis (up to 18 months) compared with placebo (moderate certainty).

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
OR 0.64 [0.16, 2.56]
1 study · 41 participants
Moderate

Dipyridamole plus aspirin vs placebo

Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dipyridamole plus aspirin vs placebo

Complications (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

Dipyridamole plus aspirin vs placebo

Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Warfarin vs placebo

Graft thrombosis (up to 3 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

Warfarin showed no clear difference in graft thrombosis (up to 37 months) compared with placebo (low certainty).

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
OR 1.76 [0.78, 3.99]
1 study · 107 participants
Low

Warfarin vs placebo

Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Warfarin vs placebo

Complications (up to 37 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Low